Target Q1 Sales Surge 6.7%, Exceeding Expectations; Turnaround Narrative Gains Support

What happened

Target's first-quarter net sales rose 6.7% year-over-year, surpassing expectations and marking a stark reversal from the -2.6% comparable sales decline in FY2025. The broad-based strength across categories, channels, and the quarter aligns with management's February claim of 'healthy, positive' sales and supports the $2B reinvestment thesis. However, the master report flagged a $543M vendor income receivable as a critical audit matter, meaning reported gross margin improvement must convert to cash to validate earnings quality. With FY2026 EPS guided at $7.50-$8.50, the Q1 beat provides near-term validation but does not yet confirm sustained comp stabilization or margin expansion beyond the ~20 bps guided improvement. The stock closed at $98.12 on May 20, below the $122.99 price in the master report, implying the market remains skeptical until consistent execution is demonstrated.

Implication

The strong Q1 provides a positive data point that the store-led reset may be gaining traction, but the master report's wait rating remains appropriate until Q2 results confirm comps turn positive and operating margin improves. Key risks include the $543M vendor income receivable collectability, higher import costs, and the end of the Ulta partnership in August. With the stock down from the master report reference price, patient investors can use further dips toward $110 as attractive entry, but conviction should remain tempered until full-year guidance is reiterated or raised.

Thesis delta

The Q1 beat increases the probability of the bull case (20% chance, $135) but does not invalidate the bear case (30%, $105) given ongoing margin and comp risks. The shift is from 'waiting for inflection' to 'inflection appearing but needing confirmation.' The core thesis—that Target's turnaround depends on sustainable comp growth and margin quality—remains unchanged, but the Q1 data nudges the balance toward the base case.